作者: Michael Moxness , Suzanna Tatarewicz , Dohan Weeraratne , Nancy Murakami , Danika Wullner
DOI: 10.1373/CLINCHEM.2005.053272
关键词:
摘要: Monitoring the immune response against human therapeutic monoclonal antibodies is an important component of preclinical and clinical trials to assess drug exposure, efficacy, safety (1)(2). Detection (analyte) directed (drug) difficult because similarity structure between analyte high concentrations present in serum, particularly during toxicology studies (3)(4). The purpose this study was develop a robust assay format applicable across species compounds for rapid method development validation. We developed 5 assays detect distinct antibody products. dependent on bivalent binding both biotin- ruthenium-conjugated (for schematic assay, see Fig. 1 Data Supplement that accompanies online version abstract at http://www.clinchem.org/content/vol51/issue10/). This “bridging” eliminated need species–specific secondary provided consistency different serum matrices as product moves from development. …